Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study describes a 62-year-old male with trichodaganomania, an urge to bite his mustache hair, who was treated with counseling and placebo medication, highlighting the need for a comprehensive treatment approach including potential psychological and psychiatric interventions if symptoms recur.

This case report highlights a rare instance of gastric trichobezoar, or "Rapunzel syndrome," associated with trichotillomania, characterized by hair accumulation in the stomach of a patient.

This case report describes a rare instance of a patient with trichotillomania also developing a gastric trichobezoar, leading to Rapunzel syndrome.

This review discusses recent advancements in behavioral and pharmacological treatments for trichotillomania but does not report new clinical results, emphasizing the need for rigorous future research.

This article highlights that isotretinoin can rarely cause persistent sexual dysfunction, similar to finasteride and certain antidepressants, a side effect not mentioned in the drug’s data sheet.

This review discusses treatment options for trichotillomania, focusing on cognitive-behavioral interventions and promising developments in combined pharmacotherapy and therapy approaches, but reports no new findings.

This case report suggests that Citalopram may cause reversible hair loss in some patients, as evidenced by hair regrowth after discontinuing the drug.

This article discusses Dr. Rajput's study on body dysmorphic disorder in hair loss patients and their improvement post-hair restoration, but it presents no original findings itself.

This study examines how conditions like PSSD, Long COVID, and ME/CFS form a "Post-Exposure Syndromes" family, initiated by transient exposures but persisting due to complex state-space dynamics, and suggests improving pharmacovigilance to better address and understand these persistent syndromes.

This presentation argues that post-exposure syndromes like PSSD and Long COVID form a coherent group of conditions driven by complex interactions in high-dimensional state spaces rather than singular molecular pathways.

This policy brief reports that post-drug syndromes like Post-Finasteride Syndrome are largely overlooked in current pharmacovigilance systems, which prioritize acute drug reactions, resulting in inadequate recognition and management of persistent medication-induced conditions.

This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions.

This paper introduces a framework attributing Post-SSRI, Post-Finasteride, Post-Retinoid, and an unnamed sexual dysfunction syndrome to downregulated estrogen receptor activity, potentially guiding future treatments in sexual medicine.

This article reviews the implications of post-SSRI sexual dysfunction syndrome and underscores the need for further epidemiological research to understand the condition and potential treatments, without offering new results.

This review discusses the off-label use of SSRIs to manage inappropriate sexual behavior in elderly dementia patients and highlights the unclear risk of post-SSRI sexual dysfunction, noting a need for high-quality clinical trials.

This study found that antidepressants may affect loving relationships differently by gender, with women on TCAs experiencing more sexual side effects and men on SSRIs reporting reduced feelings of love and attachment.

In this review, researchers analyzed literature on trichotillomania and found advances in understanding its neurobiology—highlighting dysregulated reward circuits and genetics—and treatments, with behavioral therapy and innovative pharmacological approaches improving outcomes where traditional SSRIs do not.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

Antidepressants can cause long-term side effects like severe withdrawal symptoms and sexual dysfunction, which can last for months or years after stopping the medication.

This review discusses the complex relationship between migraine and psychiatric disorders, highlighting the need for individualized treatment plans but reports no new clinical results.

This review discusses both psychiatric and medical treatments for adolescent eating disorders and highlights the need for further research, especially regarding the effectiveness of psychotropic medications in this population.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.

Eating disorders are serious, often undiagnosed conditions requiring early treatment, with anorexia being the most deadly and binge-eating the most treatable.

This case study describes a patient who developed mild eosinophilia and a skin rash after starting clozapine, which resolved without discontinuing the medication.

Finasteride use in young people may increase risk of suicidal thoughts and mental health issues.

This study found that intravaginal testosterone significantly improved sexual satisfaction and reduced dyspareunia in postmenopausal women using aromatase inhibitors, with no effect on urinary incontinence.

This study identified three symptom trajectory groups in individuals with PMDD, highlighting variations in symptom severity and duration across the luteal and follicular phases.

This study found that in a 10-week trial, inositol did not significantly reduce trichotillomania symptoms compared to placebo, although 42.1% of inositol-treated patients felt 'much or very much improved' at the study's end.

This paper discusses the use of lifestyle drugs by individuals without medical conditions to enhance appearance, highlighting that such usage may worsen emotional disorders and suggests these should be treated with psychotherapy or psychopharmacotherapy.